NDAORALCAPSULEPriority Review
Approved
Mar 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
EMEND (aprepitant) by Merck & Co. is neurokinin 1 antagonists [moa]. Approved for substance p/neurokinin-1 receptor antagonist [epc]. First approved in 2003.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMEND (aprepitant) is an oral small-molecule neurokinin-1 (NK1) receptor antagonist approved by the FDA in March 2003. It is indicated for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic cancer treatments. Aprepitant works by blocking substance P signaling in the chemoreceptor trigger zone and vomiting center, offering a novel mechanism distinct from 5-HT3 and corticosteroid-based antiemetics.
LOE Approaching1.3 years to LOE
Product is within 1.3 years of patent expiration, signaling reduced investment in commercial expansion and likely team consolidation in anticipation of generic competition.
Mechanism of Action
Neurokinin 1 Antagonists
Pharmacologic Class:
Substance P/Neurokinin-1 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Aprepitant to Improve Same Day Discharge for TKA
Started Jul 2026
350 enrolled
PONV
Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
Started Feb 2024
518 enrolled
Postoperative Nausea and Vomiting
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
Started Jul 2020
27 enrolled
COVID-19
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
Started Sep 2019
103 enrolled
Chemotherapy-induced Nausea and Vomiting
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Started Nov 2018
690 enrolled
Malignant Neoplasm
Worked on EMEND at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.